Sign Out
No formal interaction studies with Recomlyse and agents commonly administered in patients with AIS have been performed.
The use of anticoagulants (e.g., vitamin K antagonists) and anti-platelet aggregation drugs (e.g., GP IIb/IIIa antagonists) may increase the risk of bleeding prior to, during or after Recomlyse therapy.
Continue with Google